Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated
Alejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval, Araceli Tepale-Segura, Julián A. Gajón, Tania Rivera-Hernández, Eduardo Antonio Ferat-Osorio, Arturo Cérbulo‐Vázquez, Lourdes Arriaga‐Pizano, Laura C. Bonifaz, Georgina Paz-De la Rosa, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, David Sarfati-Mizrahi, , Constantino III Roberto López-Macías
This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.
Frontiers in Immunology · May 30, 2024Peer-reviewedImmunology